CA3160637A1 - Tyk2 pseudokinase ligands - Google Patents
Tyk2 pseudokinase ligandsInfo
- Publication number
- CA3160637A1 CA3160637A1 CA3160637A CA3160637A CA3160637A1 CA 3160637 A1 CA3160637 A1 CA 3160637A1 CA 3160637 A CA3160637 A CA 3160637A CA 3160637 A CA3160637 A CA 3160637A CA 3160637 A1 CA3160637 A1 CA 3160637A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pharmaceutically acceptable
- solvate
- acceptable salt
- c6alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962933179P | 2019-11-08 | 2019-11-08 | |
| US62/933,179 | 2019-11-08 | ||
| US202063046514P | 2020-06-30 | 2020-06-30 | |
| US63/046,514 | 2020-06-30 | ||
| PCT/US2020/059210 WO2021092246A1 (en) | 2019-11-08 | 2020-11-05 | Tyk2 pseudokinase ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3160637A1 true CA3160637A1 (en) | 2021-05-14 |
Family
ID=75846491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3160637A Pending CA3160637A1 (en) | 2019-11-08 | 2020-11-05 | Tyk2 pseudokinase ligands |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11753411B2 (https=) |
| EP (1) | EP4054581A4 (https=) |
| JP (1) | JP7635228B2 (https=) |
| KR (1) | KR102938141B1 (https=) |
| CN (1) | CN114929226B (https=) |
| AU (1) | AU2020378345A1 (https=) |
| BR (1) | BR112022008821A2 (https=) |
| CA (1) | CA3160637A1 (https=) |
| CL (1) | CL2022001178A1 (https=) |
| CO (1) | CO2022007814A2 (https=) |
| GE (1) | GEP20257840B (https=) |
| IL (1) | IL292785B2 (https=) |
| MX (1) | MX2022005563A (https=) |
| PH (1) | PH12022551105A1 (https=) |
| TW (1) | TWI882032B (https=) |
| UA (1) | UA129894C2 (https=) |
| WO (1) | WO2021092246A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019364336B2 (en) | 2018-10-22 | 2023-11-16 | Alumis Inc. | TYK2 inhibitors and uses thereof |
| US20220135567A1 (en) * | 2019-02-07 | 2022-05-05 | Ventyx Biosciences, Inc. | Tyk2 pseudokinase ligands |
| CA3132632A1 (en) * | 2019-03-11 | 2020-09-17 | Esker Therapeutics, Inc. | Tyk2 inhibitors and uses thereof |
| AU2020247990A1 (en) | 2019-03-26 | 2021-11-11 | Ventyx Biosciences, Inc. | TYK2 pseudokinase ligands |
| KR102938141B1 (ko) | 2019-11-08 | 2026-03-11 | 벤틱스 바이오사이언스, 인크. | Tyk2 슈도키나제 리간드 |
| KR20220140515A (ko) | 2020-01-13 | 2022-10-18 | 버지 애널리틱스, 인크. | 치환된 피라졸로-피리미딘 및 그의 용도 |
| JP2024539280A (ja) | 2021-10-25 | 2024-10-28 | カイメラ セラピューティクス， インコーポレイテッド | Ｔｙｋ２分解剤およびそれらの使用 |
| US20240010654A1 (en) * | 2022-07-06 | 2024-01-11 | Ventyx Biosciences, Inc. | Crystalline forms of a tyk2 inhibitor |
| CN120897919A (zh) * | 2023-01-13 | 2025-11-04 | 温缇克斯生物科学公司 | Tyk2抑制剂的制备 |
| CN117247389A (zh) * | 2023-09-18 | 2023-12-19 | 南京友怡医药科技有限公司 | 一种靶向药物化合物及其制备方法和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7161003B1 (en) | 2002-09-04 | 2007-01-09 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| JP4564485B2 (ja) | 2003-02-28 | 2010-10-20 | 帝人ファーマ株式会社 | ピラゾロ［１，５−ａ］ピリミジン誘導体 |
| US7538120B2 (en) * | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| US20070082900A1 (en) | 2005-10-06 | 2007-04-12 | Schering Corporation | Methods for inhibiting protein kinases |
| US8591943B2 (en) | 2009-04-09 | 2013-11-26 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors |
| NZ604708A (en) | 2010-05-20 | 2015-05-29 | Array Biopharma Inc | Macrocyclic compounds as trk kinase inhibitors |
| RS63359B1 (sr) | 2015-11-06 | 2022-07-29 | Incyte Corp | Heterociklična jedinjenja kao inhibitori pi3k-gama |
| MA46620A (fr) | 2016-10-28 | 2021-05-26 | Bristol Myers Squibb Co | Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alpha |
| JP7160824B2 (ja) | 2017-03-08 | 2022-10-25 | ニンバス ラクシュミ， インコーポレイテッド | Ｔｙｋ２阻害剤、使用およびその製造のための方法 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| SG11201910197SA (en) | 2017-05-15 | 2019-11-28 | Dana Farber Cancer Inst Inc | Compounds for treating dengue virus infection and other viral infections |
| KR102717819B1 (ko) | 2017-07-28 | 2024-10-14 | 다케다 야쿠힌 고교 가부시키가이샤 | Tyk2 억제제 및 이의 용도 |
| JP7179161B2 (ja) | 2018-09-10 | 2022-11-28 | イーライ リリー アンド カンパニー | 乾癬および全身性エリテマトーデスの処置に有用なピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド誘導体 |
| JP7619951B2 (ja) | 2018-10-15 | 2025-01-22 | 武田薬品工業株式会社 | Ｔｙｋ２阻害剤およびその使用 |
| TWI800696B (zh) | 2018-12-10 | 2023-05-01 | 美商美國禮來大藥廠 | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物 |
| US20220135567A1 (en) | 2019-02-07 | 2022-05-05 | Ventyx Biosciences, Inc. | Tyk2 pseudokinase ligands |
| CA3132632A1 (en) | 2019-03-11 | 2020-09-17 | Esker Therapeutics, Inc. | Tyk2 inhibitors and uses thereof |
| AU2020247990A1 (en) | 2019-03-26 | 2021-11-11 | Ventyx Biosciences, Inc. | TYK2 pseudokinase ligands |
| KR102938141B1 (ko) | 2019-11-08 | 2026-03-11 | 벤틱스 바이오사이언스, 인크. | Tyk2 슈도키나제 리간드 |
-
2020
- 2020-11-05 KR KR1020227018394A patent/KR102938141B1/ko active Active
- 2020-11-05 MX MX2022005563A patent/MX2022005563A/es unknown
- 2020-11-05 IL IL292785A patent/IL292785B2/en unknown
- 2020-11-05 AU AU2020378345A patent/AU2020378345A1/en active Pending
- 2020-11-05 BR BR112022008821A patent/BR112022008821A2/pt unknown
- 2020-11-05 US US17/090,805 patent/US11753411B2/en active Active
- 2020-11-05 TW TW109138709A patent/TWI882032B/zh active
- 2020-11-05 WO PCT/US2020/059210 patent/WO2021092246A1/en not_active Ceased
- 2020-11-05 UA UAA202201178A patent/UA129894C2/uk unknown
- 2020-11-05 EP EP20884019.9A patent/EP4054581A4/en active Pending
- 2020-11-05 JP JP2022525957A patent/JP7635228B2/ja active Active
- 2020-11-05 CA CA3160637A patent/CA3160637A1/en active Pending
- 2020-11-05 GE GEAP202015969A patent/GEP20257840B/en unknown
- 2020-11-05 PH PH1/2022/551105A patent/PH12022551105A1/en unknown
- 2020-11-05 CN CN202080092581.XA patent/CN114929226B/zh active Active
-
2022
- 2022-05-04 CL CL2022001178A patent/CL2022001178A1/es unknown
- 2022-06-01 CO CONC2022/0007814A patent/CO2022007814A2/es unknown
-
2023
- 2023-07-06 US US18/348,296 patent/US20230348478A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP4054581A1 (en) | 2022-09-14 |
| JP2022553841A (ja) | 2022-12-26 |
| BR112022008821A2 (pt) | 2022-08-23 |
| WO2021092246A1 (en) | 2021-05-14 |
| TWI882032B (zh) | 2025-05-01 |
| IL292785A (en) | 2022-07-01 |
| AU2020378345A1 (en) | 2022-06-02 |
| KR102938141B1 (ko) | 2026-03-11 |
| US20210139486A1 (en) | 2021-05-13 |
| EP4054581A4 (en) | 2023-11-22 |
| CO2022007814A2 (es) | 2022-09-09 |
| CN114929226A (zh) | 2022-08-19 |
| KR20220107194A (ko) | 2022-08-02 |
| TW202128698A (zh) | 2021-08-01 |
| IL292785B1 (en) | 2025-05-01 |
| PH12022551105A1 (en) | 2023-11-20 |
| UA129894C2 (uk) | 2025-09-03 |
| IL292785B2 (en) | 2025-09-01 |
| US11753411B2 (en) | 2023-09-12 |
| US20230348478A1 (en) | 2023-11-02 |
| GEP20257840B (en) | 2025-12-25 |
| MX2022005563A (es) | 2022-08-19 |
| JP7635228B2 (ja) | 2025-02-25 |
| CN114929226B (zh) | 2024-09-27 |
| CL2022001178A1 (es) | 2023-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3160637A1 (en) | Tyk2 pseudokinase ligands | |
| JP7595582B2 (ja) | Ｔｙｋ２偽キナーゼリガンド | |
| CA3129438A1 (en) | Tyk2 pseudokinase ligands | |
| KR102916168B1 (ko) | Jak 억제제 | |
| JP2022549435A (ja) | Ｊａｋ阻害剤 | |
| CA3150281A1 (en) | Jak inhibitors | |
| HK40080028A (en) | Tyk2 pseudokinase ligands | |
| HK40080028B (zh) | Tyk2假激酶配体 | |
| EA047570B1 (ru) | Лиганды псевдокиназы tyk2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20241023 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20241023 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241101 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241101 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241101 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241123 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241216 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20241216 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20241216 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241216 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250424 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250507 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20251020 |